Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04626 (
erbB-2
)
5,251
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
erbB-2
oncogene encodes a 185-kDa transmembrane protein that has been suggested to be a growth factor receptor. We have previously identified and purified a 30-kDa growth factor (gp30) that is a ligand for the p185erbB-2 protein that at high concentrations induces growth inhibition of cells with
erbB-2
amplification. We now report the purification and characterization of a protein from SKBr-3 human breast cancer cells with a molecular mass of 75 kDa (
p75
) that is a p185erbB-2 ligand. An affinity column coupled to the extracellular domain of p185erbB-2 was used for the purification. We found that
p75
induced tyrosine phosphorylation of the
erbB-2
oncoprotein, as determined by in vivo and in vitro phosphorylation and phosphoamino acid analysis.
p75
, as well as gp30, stimulated cell proliferation and colony formation of cells overexpressing
erbB-2
. The specificity of this effect was confirmed by showing that the antiproliferative effects of soluble
erbB-2
extracellular domain were reversed by either
p75
or gp30.
p75
did not show binding to the epidermal growth factor receptor and had no growth effects on cells overexpressing epidermal growth factor receptor. These data show that SKBR-3 cells, which exhibit
erbB-2
amplification and overexpression, secrete a growth factor that binds and activates p185erbB-2 specifically.
...
PMID:Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. 134 47
In order to examine the effects of the overexpression of c-
erbB-2
(HER-2, neu) on human bronchial epithelial cells, a human c-
erbB-2
expression vector was introduced into the simian virus 40 large T-antigen-immortalized human bronchial epithelial cell line BEAS-2B. Isolation of multiple clonal cell lines after selection revealed a wide range of expression of the gene product gp185erbB-2. While three of six clones tested expressed gp185erbB-2 at levels detectable by immunocytochemistry, only one, B2BE6, induced adenocarcinoma-like tumors in athymic nude mice. Both a nontumorigenic clone, B2BE2, and a tumorigenic clone, B2BE6, expressed comparable amounts of gp185erbB-2, which became phosphorylated on tyrosine in response to treatment with the c-
erbB-2
ligands gp30 and
p75
. These data suggest that overexpression of c-
erbB-2
in human bronchial epithelial cells can contribute to, but is not sufficient for, induction of tumorigenicity in this human model system.
...
PMID:Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. 768 50
Our previous studies have demonstrated that 7 of 10 IgG antibodies against distinct epitopes on the extracellular domain of the c-
erbB-2
gene product (p185) inhibit the anchorage-independent growth of SKBr3 human breast-cancer cells that overexpress this transmembrane tyrosine kinase growth-factor receptor. Two of 7 growth-inhibitory antibodies also block the binding and function of the gp30 and
p75
c-
erbB-2
ligands. In this report we have studied phosphorylation of p185 and different intracellular substrates after binding of antibodies that do or do not inhibit tumor-cell growth. A correlation has been found between antibodies that inhibit growth and the intensity of tyrosine phosphorylation of p185. At late intervals, serine phosphorylation of at least 3 intracellular substrates is increased preferentially by growth-inhibitory antibodies. To test the importance of p185 kinase activity more critically, NIH3T3 cells were transfected with an expression vector containing the full-length human c-
erbB-2
gene (cell line 17313), c-
erbB-2
with deletion of the kinase region from codons 751-979 (cell line 9309) or c-
erbB-2
with deletion of most of the intracellular domain from codons 684-1255 (cell line 9310). Unconjugated antibodies inhibited anchorage-independent growth of 17313 cells as well as SKBr3 cells, but did not inhibit growth of either 9309 or 9310 cells. In contrast, the cytotoxic effect of anti-p185-ricin A chain (RTA) conjugates was comparable for 17313, 9309 and 9310. The tyrosine-kinase activity of p185 is required for growth inhibition mediated by unconjugated anti-p185 antibodies, but not for the cytotoxic activity of anti-p185-RTA immunotoxins.
...
PMID:The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. 792 25